No Detail Found!

Outcomes of Pioglitazone and Metformin on Anthropometric, Metabolic and Endocrine variables in Polycystic Ovary Syndrome

Author(s)
AYESHA KHAN Bahria University Medical and Dental College, Sailor Street, Phase-II DHA, Karachi, Pakistan
MAMOORA ARSLAAN Islamabad Medical and Dental College, Murree Rd, Bhara Kahu, Islamabad, Pakistan
ASRA KHAN PAHORE Pharmacology Department, Altamash Institute of Dental Medicine, ST-2B, Shahrah-e-Firdousi, Block 3 Clifton, Karachi, Pakistan
HAFIZA TUSEEF SAYYAR Physical Therapy, Bahria University College of Physical Therapy,Adjacent PNS Shifa, DHA, Karachi, Pakistan
NASIM KARIM Bahria University Medical & Dental College,Adjacent PNS Shifa, DHA, Karachi, Pakistan
Abstract
Aim: To evaluate the outcomes of Pioglita zone and Metformin on anthropometric, metabolic and endocrine variables in PCOS. Methods: This randomized controlled trial was executed at Pharmacology Department of Bahria University Medical and Dental College in collaboration with Mamji Hospital Karachi from September 2018 to March 2019. Eighty PCOS infertile patients as per Rotterdam 2003 criteria,aged 20-40 years were enrolled. They were divided into two groups of 40 patients each by using computer generated numbers. All patients had fasting insulin levels of >9 µU/mL, serum glucose levels =126 mg/dl and suffering from oligomenorrhoea or amenorrhoea. Group A received Tablet Pioglitazone 30 mg once daily and group B was given tablet Metformin 500 mg for three months along with lifestyle changes. Results: Sixty-one participants completed the study. Anthropometric variables included weight, BMI and W/H ratio. Metformin treated group reduced more weight and BMI as compared to Pioglitazone. Metabolic variables included glycaemic indices, lipid profile and hs-CRP estimation. Pioglitazone group improved glycaemic indices more compared to Metformin. Serum progesterone level was significantly increased in Pioglitazone group (5.20±1.18) than Metformin group. Pioglitazone produced more ovulation in comparison to Metformin. Hence it is proved that it is better option in those patients who are unable to tolerate Metformin and cannot continue treatment for infertility. Conclusion: Pioglitazone group produced highly significant increase in serum progesterone level indicating ovulation and improved insulin resistance than the metformin group.
Publication Details
Page(s) 220-222
Published Journal: Pakistan Journal of Medical and Health Sciences, Volume: 17, Issue: 1, Year: 2023

Request the full text from PASTIC

Keywords
metformin, Ovulation induction, Polycystic Ovarian Syndrome, Pioglitazone, Female infertility
0

Citations

0

Downloads

97

Views